Clinical trial · Interventional
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease
NCT00812266CI-TRIAL-00020665terminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual
Summary
Brief summary (as posted)
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive Disease | — | UNRESOLVED | — |
| First-Line | — | UNRESOLVED | — |
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Etoposide + carboplatin | Drug | — | UNRESOLVED |
| topotecan + cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A
- description
- Topotecan + cisplatin
- interventionNames
- Drug: topotecan + cisplatin
- type
- ACTIVE_COMPARATOR
- label
- B
- description
- Etoposide + carboplatin
- interventionNames
- Drug: Etoposide + carboplatin
Primary outcomes (1)
- measure
- 2 years survival
- timeFrame
- 2 years
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed SCLC * Extensive stage * No prior chemotherapy * WHO PS 0-3 * Adequate organ function (liver, kidney) * Adequate hematology (bone marrow) * Informed consent Exclusion Criteria: * PS 4 * Inadequate organ function * Uncontrolled infection * Concomitant major medical contraindications
References
Publications (0)
Data not yet available
No reference posted for this study.